bluuebunny/crossref_metadata_2025_split huggingface dataset:
MO‐AB‐204‐02: IHE RAD
Authors: Seibert J. 
Published: July 2016

You've experienced the frustration: vendor A's device claims to work with vendor B's device, but the practice doesn't match the promise. Getting devices working together is the hidden art that Radiology and Radiation Oncology staff have to master. To assist with that difficult process, the Integrating the Healthcare Enterprise (IHE) effort was established in 1998, with the coordination of the Radiological Society of North America.Integrating the Healthcare Enterprise (IHE) is a consortium of healthcare professionals and industry partners focused on improving the way computer systems interconnect and exchange information. This is done by coordinating the use of published standards like DICOM and HL7. Several clinical and operational IHE domains exist in the healthcare arena, including Radiology and Radiation Oncology. The ASTRO‐sponsored IHE Radiation Oncology (IHE‐RO) domain focuses on radiation oncology specific information exchange. This session will explore the IHE Radiology and IHE RO process for;

IHE solicitation process for new profiles.
Improving the way computer systems interconnect and exchange information in the healthcare enterprise
Supporting interconnectivity descriptions and proof of adherence by vendors
Testing and assuring the vendor solutions to connectivity problems.
Including IHE profiles in RFPs for future software and hardware purchases.
Learning Objectives:
Understand IHE role in improving interoperability in health care.
Understand process of profile development and implantation.
Understand how vendors prove adherence to IHE RO profiles.S. Hadley, ASTRO Supported Activity
MO‐AB‐204‐04: Connectathons and Testing
Authors: Bosch W. 
Published: July 2016

You've experienced the frustration: vendor A's device claims to work with vendor B's device, but the practice doesn't match the promise. Getting devices working together is the hidden art that Radiology and Radiation Oncology staff have to master. To assist with that difficult process, the Integrating the Healthcare Enterprise (IHE) effort was established in 1998, with the coordination of the Radiological Society of North America.Integrating the Healthcare Enterprise (IHE) is a consortium of healthcare professionals and industry partners focused on improving the way computer systems interconnect and exchange information. This is done by coordinating the use of published standards like DICOM and HL7. Several clinical and operational IHE domains exist in the healthcare arena, including Radiology and Radiation Oncology. The ASTRO‐sponsored IHE Radiation Oncology (IHE‐RO) domain focuses on radiation oncology specific information exchange. This session will explore the IHE Radiology and IHE RO process for;

IHE solicitation process for new profiles.
Improving the way computer systems interconnect and exchange information in the healthcare enterprise
Supporting interconnectivity descriptions and proof of adherence by vendors
Testing and assuring the vendor solutions to connectivity problems.
Including IHE profiles in RFPs for future software and hardware purchases.
Learning Objectives:
Understand IHE role in improving interoperability in health care.
Understand process of profile development and implantation.
Understand how vendors prove adherence to IHE RO profiles.S. Hadley, ASTRO Supported Activity
MO‐A‐BRB‐01: TG191: Clinical Use of Luminescent Dosimeters
Authors: Kry S. 
Published: July 2016

This presentation will highlight the upcoming TG‐191 report: Clinical Use of Luminescent Dosimeters. Luminescent dosimetry based on TLD and OSLD is a practical, accurate, and precise technique for point dosimetry in medical physics applications. The charges of Task Group 191 were to detail the methodologies for practical and optimal luminescent dosimetry in a clinical setting. This includes (1) To review the variety of TLD/OSL materials available, including features and limitations of each. (2) To outline the optimal steps to achieve accurate and precise dosimetry with luminescent detectors and to evaluate the uncertainty induced when less rigorous procedures are used. (3) To develop consensus guidelines on the optimal use of luminescent dosimeters for clinical practice. (4) To develop guidelines for special medically relevant uses of TLDs/OSLs (e.g., mixed field i.e. photon/neutron dosimetry, particle beam dosimetry, skin dosimetry). While this report provides general guidelines for arbitrary TLD and OSLD processes, the report, and therefore this presentation, provide specific guidance for TLD‐100 (LiF:Ti,Mg) and nanoDot (Al2O3:C) dosimeters because of their prevalence in clinical practice.

Learning Objectives:
Understand the available dosimetry systems, and basic theory of their operation
Understand the range of dose determination methodologies and the uncertainties associated with them
Become familiar with special considerations for TLD/OSLD relevant for special clinical situations
Learn recommended commissioning and QA procedures for these dosimetry systems.
MO‐AB‐BRA‐04: Radiation Measurements with a DNA Double‐Strand‐Break Dosimeter
Authors: Obeidat M , Cline K , Stathakis S , Papanikolaou N , Rasmussen K , Gutierrez A , Ha CS , Lee SE , Shim EY , Kirby N 
Published: July 2016

Purpose:Many types of dosimeters are used to measure radiation, but none of them directly measures the biological effect of this dose. The purpose here is to create a dosimeter that can measure the probability of double‐strand breaks (DSB) for DNA, which is directly related to the biological effect of radiation.Methods:The dosimeter has DNA strands, which are labeled on one end with biotin and on the other with fluorescein. The biotin attaches these strands to magnetic beads. We suspended the DNA dosimeter in phosphate‐buffered saline (PBS) as it matches the internal environment of the body. We placed small volumes (50µL) of the DNA dosimeter into tubes and irradiated these samples in a water‐equivalent plastic phantom with several doses (three samples per dose). After irradiating the samples, a magnet was placed against the tubes. The fluorescein attached to broken DNA strands was extracted (called the supernatant) and placed into a different tube. The fluorescein on the unbroken strands remained attached to the beads in the tube and was re‐suspended with 50µL of PBS. A fluorescence reader was used to measure the fluorescence for both the re‐suspended beads and supernatant. To prove that we are measuring DSB, we tested dosimeter response with two different lengths of attached DNA strands (1 and 4 kilo‐base pair).Results:The probability of DSB at the dose levels of 5, 10, 25, and 50 Gy were 0.05, 0.08, 0.12, and 0.19, respectively, while the coefficients of variation were 0.14, 0.07, 0.02, and 0.01, respectively. The 4 kilo‐base‐pair dosimeter produced 5.3 times the response of the 1 kilo‐base‐pair dosimeter.Conclusion:The DNA dosimeter yields a measurable response to dose that scales with the DNA strand length. The goal now is to refine the dosimeter fabrication to reproducibly create a low coefficient of variation for the lower doses.This work was supported in part by Yarmouk University (Irbid, Jordan) and CPRIT (RP140105)
MO‐AB‐BRA‐10: Super High Temporal Resolution Cardiac CT Imaging Using SMART‐RECON
Authors: Li Y , Cao X , Xing Z , Sun X , Hsieh J , Chen G 
Published: July 2016

Purpose:Coronary CT angiography is a challenging task currently limited by the achievable temporal resolution of modern MDCT scanners. In this work, a highly innovative method has been developed and validated to improve temporal resolution of the MDCT by a factor of four with the newly developed SMART‐RECON method to enable high quality coronary CTA exams. The primary purpose of this paper is to investigate the relationships between: (1) SMART‐RECON and the motion pattern; (2) SMART‐RECON and the average speed of moving vessels; (3) SMART‐RECON and the position and direction of moving vessels.Methods:Using data acquired from a short scan angular range, the entire cardiac window is divided into 4–5 narrower cardiac windows, each corresponding to a 60‐degree angular sector. These 4–5 sub‐cardiac phase images can be jointly reconstructed with SMART‐RECON to globally improve temporal resolution and noise properties. A hybrid phantom consisting of realistic cardiac anatomy and eight moving objects was constructed to validate the method under a wide variety of conditions and studied quantitatively. Additionally, in vivo data from twenty human subjects were used to demonstrate that SMART‐RECON can significantly improve the quality of CTA using a Discovery CT 750 HD (GE Healthcare, WI, USA) with 350 ms gantry rotation time.Results:The performance of the proposed SMART‐RECON cardiac CT imaging method is independent of motion speed, orientation, and location as long as there is a motionless phase that corresponds to 60° angular range. In contrast, the currently available FBP cardiac reconstruction with Parker weights demonstrates significant motion artifacts. The human subject results also demonstrate the significant improvement of coronary CTA quality cross all subjects.Conclusion:With a single short‐scan acquisition, SMART‐RECON can be used to systematically improve the temporal resolution for MDCT cardiac CT imaging by a factor of 4 with no prior knowledge of motion.Funding support: This work was support in part by GE Healthcare. Disclosures: Y. Li: None. X. Cao, Z. Xing, X. Sun and H. Jiang: GE employee. G. Chen: Research contract with GE Healthcare; Research contract with Siemens AX; Royalty received from GE Healthcare
MO‐AB‐206‐02: Testing Gamma Cameras Based On TG177 WG Report
Authors: Halama J. 
Published: July 2016

This education session will cover the physics and operation principles of gamma cameras and PET scanners.The first talk will focus on PET imaging. An overview of the principles of PET imaging will be provided, including positron decay physics, and the transition from 2D to 3D imaging. More recent advances in hardware and software will be discussed, such as time‐of‐flight imaging, and improvements in reconstruction algorithms that provide for options such as depth‐of‐interaction corrections. Quantitative applications of PET will be discussed, as well as the requirements for doing accurate quantitation. Relevant performance tests will also be described.

Learning Objectives:
Be able to describe basic physics principles of PET and operation of PET scanners.
Learn about recent advances in PET scanner hardware technology.
Be able to describe advances in reconstruction techniques and improvements
Be able to list relevant performance tests.The second talk will focus on gamma cameras. The Nuclear Medicine subcommittee has charged a task group (TG177) to develop a report on the current state of physics testing of gamma cameras, SPECT, and SPECT/CT systems. The report makes recommendations for performance tests to be done for routine quality assurance, annual physics testing, and acceptance tests, and identifies those needed satisfy the ACR accreditation program and The Joint Commission imaging standards. The report is also intended to be used as a manual with detailed instructions on how to perform tests under widely varying conditions.Learning Objectives:At the end of the presentation members of the audience will:

Be familiar with the tests recommended for routine quality assurance, annual physics testing, and acceptance tests of gamma cameras for planar imaging.
Be familiar with the tests recommended for routine quality assurance, annual physics testing, and acceptance tests of SPECT systems.
Be familiar with the tests of a SPECT/CT system that include the CT images for SPECT reconstructions.
Become knowledgeable of items to be included in annual acceptance testing reports including CT dosimetry and PACS monitor measurements.T. Turkington, GE Healthcare
MO‐A‐209‐01: AAPM Journal Finances: Facts, Figures, and Fundamentals
Authors: Armato S. 
Published: July 2016

Scientific publishing is a major endeavor of the AAPM. Although publishing requires substantial resources, it has the potential to generate both reputation and revenue to further the missions of our society. The AAPM owns and publishes two journals: Medical Physics and the Journal of Applied Clinical Medical Physics (JACMP). Medical Physics, with the tagline “The international journal of medical physics research and practice,” publishes research concerned with the application of physics and mathematics to the solution of problems in medicine and human biology, with an emphasis on theoretical and experimental approaches. The JACMP is an applied journal that publishes papers designed to help clinical medical physicists perform their responsibilities more effectively and efficiently for the greater benefit of patients. The two journals reflect two different missions, reach two different (yet often overlapping) audiences, engage two different publication approaches, and operate under two different financial models. A journal must serve both “producers” (authors who submit manuscripts to – and ultimately have their work published in – the journal) and “consumers” (readers – either individuals who access journal content or subscribing institutions that make the journal's content available to its members). Any viable publication model and cost‐recovery structure must satisfy the interests of both groups without sacrificing the needs of the scientific community. The purpose of this symposium is to explore the roles of the AAPM's two journals in advancing the scientific and clinical missions of the society and to understand the complex interplay of economic factors that impact financial decisions governing the journals and the returns they bring to the AAPM.

Learning Objectives:
Appreciate the complementary roles of Medical Physics and JACMP in advancing the scientific and clinical missions of the AAPM.
Understand AAPM resources committed to the two journals and the return on these investments.
Understand the role of the AAPM's Journals Business Management Committee in the financial stability of the two journals.
Explore the potential benefits and pitfalls of various economic and publication models for the two journals.J. Bourland, Member, Journals Business Management Committee, AAPM.
MO‐B‐201‐00: Motion Management in Current Stereotactic Body Radiation Therapy (SBRT) Practice
Authors: Shang Charles 
Published: July 2016

The motion management in stereotactic body radiation therapy (SBRT) is a key to success for a SBRT program, and still an on‐going challenging task. A major factor is that moving structures behave differently than standing structures when examined by imaging modalities, and thus require special considerations and employments. Understanding the motion effects to these different imaging processes is a prerequisite for a decent motion management program. The commonly used motion control techniques to physically restrict tumor motion, if adopted correctly, effectively increase the conformity and accuracy of hypofractionated treatment. The effective application of such requires one to understand the mechanics of the application and the related physiology especially related to respiration. The image‐guided radiation beam control, or tumor tracking, further realized the endeavor for precision‐targeting. During tumor tracking, the respiratory motion is often constantly monitored by non‐ionizing beam sources using the body surface as its surrogate. This then has to synchronize with the actual internal tumor motion. The latter is often accomplished by stereo X‐ray imaging or similar techniques. With these advanced technologies, one may drastically reduce the treated volume and increase the clinicians’ confidence for a high fractional ablative radiation dose. However, the challenges in implementing the motion management may not be trivial and is dependent on each clinic case. This session of presentations is intended to provide an overview of the current techniques used in managing the tumor motion in SBRT, specifically for routine lung SBRT, proton based treatments, and newly‐developed MR guided RT.Learning Objectives:Through this presentation, the audience will

understand basic roles of commonly used imaging modalities for lung cancer studies;
familiarize the major advantages and limitations of each discussed motion control methods;
familiarize the major advantages and limitations of each discussed radiation beam control methodology and tumor tacking method;
understand the key points in motion management for a high quality SBRT program.
MO‐B‐201‐03: MRI‐Guided Tracking and Gating
Authors: Green O. 
Published: July 2016

The motion management in stereotactic body radiation therapy (SBRT) is a key to success for a SBRT program, and still an on‐going challenging task. A major factor is that moving structures behave differently than standing structures when examined by imaging modalities, and thus require special considerations and employments. Understanding the motion effects to these different imaging processes is a prerequisite for a decent motion management program. The commonly used motion control techniques to physically restrict tumor motion, if adopted correctly, effectively increase the conformity and accuracy of hypofractionated treatment. The effective application of such requires one to understand the mechanics of the application and the related physiology especially related to respiration. The image‐guided radiation beam control, or tumor tracking, further realized the endeavor for precision‐targeting. During tumor tracking, the respiratory motion is often constantly monitored by non‐ionizing beam sources using the body surface as its surrogate. This then has to synchronize with the actual internal tumor motion. The latter is often accomplished by stereo X‐ray imaging or similar techniques. With these advanced technologies, one may drastically reduce the treated volume and increase the clinicians’ confidence for a high fractional ablative radiation dose. However, the challenges in implementing the motion management may not be trivial and is dependent on each clinic case. This session of presentations is intended to provide an overview of the current techniques used in managing the tumor motion in SBRT, specifically for routine lung SBRT, proton based treatments, and newly‐developed MR guided RT.Learning Objectives:Through this presentation, the audience will

understand basic roles of commonly used imaging modalities for lung cancer studies;
familiarize the major advantages and limitations of each discussed motion control methods;
familiarize the major advantages and limitations of each discussed radiation beam control methodology and tumor tacking method;
understand the key points in motion management for a high quality SBRT program.
MO‐B‐BRB‐02: 3D Dosimetry in the Clinic: IMRT Technique Validation in Sweden
Authors: Ceberg S. 
Published: July 2016

Full three‐dimensional (3D) dosimetry using volumetric chemical dosimeters probed by 3D imaging systems has long been a promising technique for the radiation therapy clinic, since it provides a unique methodology for dose measurements in the volume irradiated using complex conformal delivery techniques such as IMRT and VMAT. To date true 3D dosimetry is still not widely practiced in the community; it has been confined to centres of specialized expertise especially for quality assurance or commissioning roles where other dosimetry techniques are difficult to implement. The potential for improved clinical applicability has been advanced considerably in the last decade by the development of improved 3D dosimeters (e.g., radiochromic plastics, radiochromic gel dosimeters and normoxic polymer gel systems) and by improved readout protocols using optical computed tomography or magnetic resonance imaging.In this session, established users of some current 3D chemical dosimeters will briefly review the current status of 3D dosimetry, describe several dosimeters and their appropriate imaging for dose readout, present workflow procedures required for good dosimetry, and analyze some limitations for applications in select settings. We will review the application of 3D dosimetry to various clinical situations describing how 3D approaches can complement other dose delivery validation approaches already available in the clinic. The applications presented will be selected to inform attendees of the unique features provided by full 3D techniques.

Learning Objectives:
L. John Schreiner: Background and Motivation

Understand recent developments enabling clinically practical 3D dosimetry,
Appreciate 3D dosimetry workflow and dosimetry procedures, and
Observe select examples from the clinic.
Sofie Ceberg: Application to dynamic radiotherapy

Observe full dosimetry under dynamic radiotherapy during respiratory motion, and
Understand how the measurement of high resolution dose data in an irradiated volume can help understand interplay effects during TomoTherapy or VMAT.
Titania Juang: Special techniques in the clinic and research

Understand the potential for 3D dosimetry in validating dose accumulation in deformable systems, and
Observe the benefits of high resolution measurements for precision therapy in SRS and in MicroSBRT for small animal irradiators
Geoffrey S. Ibbott: 3D Dosimetry in end‐to‐end dosimetry QA

Understand the potential for 3D dosimetry for end‐to‐end radiation therapy process validation in the in‐house and external credentialing setting.Canadian Institutes of Health Research; L. Schreiner, Modus QA, London, ON, Canada; T. Juang, NIH R01CA100835